WuXi Biologics (Cayman) Inc.

SEHK:2269 Stock Report

Market Cap: HK$123.8b

WuXi Biologics (Cayman) Valuation

Is 2269 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of 2269 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: 2269 (HK$29.94) is trading below our estimate of future cash flow value (HK$55.73)

Significantly Below Future Cash Flow Value: 2269 is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2269?

Key metric: As 2269 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 2269. This is calculated by dividing 2269's market cap by their current earnings.
What is 2269's PE Ratio?
PE Ratio21.8x
EarningsCN¥4.91b
Market CapCN¥107.02b

Price to Earnings Ratio vs Peers

How does 2269's PE Ratio compare to its peers?

The above table shows the PE ratio for 2269 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average23x
2268 WuXi XDC Cayman
33.8x25.29%HK$57.8b
3880 Medtide
12.1xn/aHK$3.0b
1521 Frontage Holdings
36.2x25.00%HK$1.9b
1873 Viva Biotech Holdings
9.8x26.34%HK$2.5b
2269 WuXi Biologics (Cayman)
21.8x13.83%HK$123.8b

Price-To-Earnings vs Peers: 2269 is good value based on its Price-To-Earnings Ratio (21.8x) compared to the peer average (31.8x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does 2269's PE Ratio compare vs other companies in the Asian Life Sciences Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
2269 21.8xIndustry Avg. 33.9xNo. of Companies7PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 2269 is good value based on its Price-To-Earnings Ratio (21.8x) compared to the Asian Life Sciences industry average (34.2x).

Price to Earnings Ratio vs Fair Ratio

What is 2269's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2269 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio21.8x
Fair PE Ratio19.9x

Price-To-Earnings vs Fair Ratio: 2269 is expensive based on its Price-To-Earnings Ratio (21.8x) compared to the estimated Fair Price-To-Earnings Ratio (19.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 2269 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentHK$29.94
HK$46.88
+56.57%
18.16%HK$78.47HK$30.60n/a22
Jun ’27HK$34.62
HK$46.88
+35.40%
18.19%HK$78.52HK$30.62n/a22
May ’27HK$33.04
HK$46.02
+39.28%
18.98%HK$77.70HK$30.30n/a21
Apr ’27HK$34.86
HK$44.42
+27.42%
12.75%HK$54.61HK$30.04n/a23
Mar ’27HK$40.22
HK$45.34
+12.73%
14.02%HK$54.69HK$31.38n/a23
Feb ’27HK$37.00
HK$40.98
+10.76%
14.48%HK$52.06HK$30.69n/a25
Jan ’27HK$31.44
HK$39.54
+25.77%
14.53%HK$52.26HK$30.30n/a25
Dec ’26HK$31.72
HK$39.38
+24.15%
14.61%HK$52.40HK$30.09n/a25
Nov ’26HK$36.20
HK$38.60
+6.64%
14.74%HK$51.91HK$29.88n/a25
Oct ’26HK$40.98
HK$37.58
-8.30%
14.57%HK$50.20HK$28.11n/a26
Sep ’26HK$35.98
HK$36.59
+1.70%
12.35%HK$50.19HK$28.11n/a26
Aug ’26HK$31.35
HK$30.73
-1.97%
17.53%HK$44.86HK$20.19n/a26
Jul ’26HK$25.65
HK$29.80
+16.17%
17.95%HK$46.03HK$20.22n/a26
Jun ’26HK$24.95
HK$29.16
+16.86%
19.78%HK$45.76HK$18.29HK$34.6226
May ’26HK$22.80
HK$28.68
+25.80%
19.76%HK$44.74HK$17.89HK$33.0426
Apr ’26HK$26.80
HK$28.32
+5.67%
24.36%HK$45.00HK$9.97HK$34.8624
Mar ’26HK$22.45
HK$22.52
+0.32%
30.48%HK$35.02HK$9.82HK$40.2225
Feb ’26HK$18.42
HK$20.96
+13.79%
30.94%HK$35.00HK$9.81HK$37.0025
Jan ’26HK$17.56
HK$19.55
+11.36%
37.01%HK$34.18HK$9.77HK$31.4424
Dec ’25HK$15.00
HK$18.87
+25.79%
38.72%HK$34.46HK$9.85HK$31.7225
Nov ’25HK$16.32
HK$19.43
+19.08%
39.83%HK$34.98HK$9.99HK$36.2026
Oct ’25HK$17.50
HK$19.56
+11.79%
43.80%HK$42.50HK$10.15HK$40.9826
Sep ’25HK$11.22
HK$19.28
+71.82%
44.78%HK$42.15HK$8.53HK$35.9826
Aug ’25HK$11.42
HK$21.34
+86.83%
38.52%HK$42.03HK$8.50HK$31.3525
Jul ’25HK$11.54
HK$22.64
+96.15%
44.86%HK$53.20HK$11.91HK$25.6525
Jun ’25HK$11.14
HK$26.44
+137.32%
58.19%HK$73.15HK$11.95HK$24.9526
HK$46.88
Fair Value
36.1% undervalued intrinsic discount
22
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/11 07:04
End of Day Share Price 2026/06/11 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

WuXi Biologics (Cayman) Inc. is covered by 50 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nithya BalasubramanianBernstein
Bo LiBofA Global Research
Zhishun SiuCCB International Securities Limited